Naresh Mandava
Concepts (360)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Macular Degeneration | 21 | 2023 | 152 | 5.350 |
Why?
| Geographic Atrophy | 7 | 2023 | 51 | 2.390 |
Why?
| Visual Acuity | 18 | 2023 | 275 | 2.280 |
Why?
| Retinal Detachment | 6 | 2023 | 55 | 2.250 |
Why?
| Diabetic Retinopathy | 11 | 2023 | 156 | 2.100 |
Why?
| Wet Macular Degeneration | 5 | 2023 | 32 | 1.920 |
Why?
| Angiogenesis Inhibitors | 17 | 2023 | 223 | 1.890 |
Why?
| Retinal Drusen | 3 | 2021 | 25 | 1.760 |
Why?
| Registries | 4 | 2020 | 2020 | 1.280 |
Why?
| Vitreous Body | 15 | 2022 | 104 | 1.240 |
Why?
| Vitrectomy | 12 | 2020 | 58 | 1.200 |
Why?
| Macula Lutea | 2 | 2023 | 15 | 1.140 |
Why?
| Retina | 10 | 2021 | 277 | 0.970 |
Why?
| Retinal Diseases | 4 | 2023 | 81 | 0.910 |
Why?
| Antibodies, Monoclonal | 9 | 2011 | 1306 | 0.900 |
Why?
| Vascular Endothelial Growth Factor A | 12 | 2023 | 537 | 0.900 |
Why?
| Retinal Neovascularization | 2 | 2019 | 21 | 0.830 |
Why?
| Choroidal Neovascularization | 6 | 2019 | 45 | 0.820 |
Why?
| Fluorescein Angiography | 15 | 2023 | 103 | 0.800 |
Why?
| National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.790 |
Why?
| Retinal Perforations | 4 | 2015 | 14 | 0.760 |
Why?
| Quarantine | 1 | 2020 | 26 | 0.750 |
Why?
| Estrogen Replacement Therapy | 1 | 2019 | 118 | 0.670 |
Why?
| Retinitis Pigmentosa | 3 | 2021 | 17 | 0.650 |
Why?
| Tomography, Optical Coherence | 10 | 2022 | 134 | 0.650 |
Why?
| Automobile Driving | 1 | 2018 | 129 | 0.590 |
Why?
| Epiretinal Membrane | 3 | 2010 | 6 | 0.580 |
Why?
| Intraocular Pressure | 6 | 2012 | 286 | 0.580 |
Why?
| Aged, 80 and over | 15 | 2021 | 6845 | 0.560 |
Why?
| Aged | 27 | 2023 | 20495 | 0.550 |
Why?
| Scleral Buckling | 3 | 2019 | 19 | 0.540 |
Why?
| Antibodies, Monoclonal, Humanized | 11 | 2015 | 658 | 0.520 |
Why?
| Self Report | 1 | 2018 | 730 | 0.500 |
Why?
| Optic Neuropathy, Ischemic | 3 | 2013 | 29 | 0.500 |
Why?
| Humans | 76 | 2023 | 122796 | 0.490 |
Why?
| Recombinant Fusion Proteins | 4 | 2013 | 661 | 0.470 |
Why?
| Choroid | 5 | 2021 | 47 | 0.460 |
Why?
| Retinopathy of Prematurity | 3 | 2020 | 111 | 0.450 |
Why?
| Female | 46 | 2023 | 63629 | 0.450 |
Why?
| Surveys and Questionnaires | 4 | 2022 | 4882 | 0.450 |
Why?
| Bevacizumab | 11 | 2015 | 127 | 0.450 |
Why?
| Research Design | 1 | 2019 | 1002 | 0.440 |
Why?
| Follow-Up Studies | 13 | 2021 | 4768 | 0.440 |
Why?
| Retinal Necrosis Syndrome, Acute | 2 | 2013 | 9 | 0.420 |
Why?
| Male | 44 | 2023 | 59639 | 0.420 |
Why?
| Retinal Vein Occlusion | 2 | 2015 | 13 | 0.420 |
Why?
| Pandemics | 1 | 2020 | 1401 | 0.410 |
Why?
| Photography | 4 | 2015 | 96 | 0.410 |
Why?
| Endophthalmitis | 3 | 2017 | 25 | 0.400 |
Why?
| Uveal Diseases | 2 | 2013 | 5 | 0.400 |
Why?
| Cataract | 2 | 2020 | 194 | 0.390 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2015 | 35 | 0.380 |
Why?
| Middle Aged | 28 | 2021 | 28563 | 0.380 |
Why?
| Colorado | 7 | 2023 | 4325 | 0.360 |
Why?
| Complement Factor B | 2 | 2022 | 102 | 0.360 |
Why?
| Visual Fields | 3 | 2022 | 79 | 0.360 |
Why?
| Glycogen Storage Disease Type IIb | 2 | 2007 | 20 | 0.360 |
Why?
| Vision, Low | 4 | 2022 | 13 | 0.350 |
Why?
| Pigment Epithelium of Eye | 2 | 2006 | 34 | 0.350 |
Why?
| Injections | 6 | 2010 | 171 | 0.340 |
Why?
| Complement Activation | 3 | 2022 | 349 | 0.340 |
Why?
| Prospective Studies | 7 | 2023 | 6704 | 0.340 |
Why?
| Ophthalmology | 2 | 2013 | 77 | 0.330 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 1213 | 0.330 |
Why?
| Ocular Hypertension | 1 | 2009 | 60 | 0.330 |
Why?
| Retrospective Studies | 22 | 2023 | 13433 | 0.320 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2007 | 56 | 0.310 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2007 | 12 | 0.310 |
Why?
| Optic Nerve Injuries | 1 | 2007 | 4 | 0.310 |
Why?
| Macular Edema | 2 | 2015 | 37 | 0.310 |
Why?
| Phacoemulsification | 3 | 2020 | 104 | 0.310 |
Why?
| Quantum Dots | 2 | 2021 | 35 | 0.300 |
Why?
| Encephalitis, Herpes Simplex | 1 | 2007 | 22 | 0.300 |
Why?
| Papilledema | 1 | 2007 | 36 | 0.300 |
Why?
| Vision Disorders | 2 | 2022 | 134 | 0.300 |
Why?
| von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.300 |
Why?
| Fovea Centralis | 2 | 2010 | 8 | 0.300 |
Why?
| Puerperal Disorders | 1 | 2007 | 34 | 0.290 |
Why?
| Glucocorticoids | 2 | 2013 | 554 | 0.290 |
Why?
| RNA, Catalytic | 1 | 2007 | 182 | 0.290 |
Why?
| Triamcinolone Acetonide | 1 | 2006 | 24 | 0.290 |
Why?
| Herpesvirus 1, Human | 1 | 2007 | 82 | 0.280 |
Why?
| Ocular Hypotension | 1 | 2006 | 11 | 0.280 |
Why?
| Ciliary Body | 1 | 2006 | 34 | 0.280 |
Why?
| Myopia | 1 | 2006 | 37 | 0.280 |
Why?
| Telangiectasis | 1 | 2005 | 6 | 0.270 |
Why?
| Granuloma | 1 | 2006 | 93 | 0.270 |
Why?
| Chemokine CCL5 | 2 | 2023 | 50 | 0.270 |
Why?
| Retinal Vessels | 1 | 2005 | 53 | 0.260 |
Why?
| DNA, Viral | 1 | 2007 | 358 | 0.260 |
Why?
| Retinal Ganglion Cells | 4 | 2022 | 92 | 0.260 |
Why?
| Laser Therapy | 2 | 2021 | 105 | 0.250 |
Why?
| Diabetes Mellitus | 2 | 2023 | 985 | 0.250 |
Why?
| Vision Tests | 1 | 2023 | 15 | 0.240 |
Why?
| Fluorocarbons | 1 | 2005 | 106 | 0.240 |
Why?
| Temporal Arteries | 2 | 2015 | 47 | 0.230 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 3 | 2013 | 105 | 0.230 |
Why?
| Disease Models, Animal | 4 | 2012 | 3799 | 0.220 |
Why?
| Hemianopsia | 1 | 2022 | 10 | 0.220 |
Why?
| Risk Factors | 9 | 2023 | 9381 | 0.210 |
Why?
| Optic Disk | 3 | 2010 | 37 | 0.210 |
Why?
| Ophthalmoscopy | 2 | 2015 | 30 | 0.210 |
Why?
| Posterior Capsulotomy | 1 | 2021 | 8 | 0.200 |
Why?
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.200 |
Why?
| Lasers, Solid-State | 1 | 2021 | 24 | 0.200 |
Why?
| Capsule Opacification | 1 | 2021 | 27 | 0.200 |
Why?
| Cross-Sectional Studies | 4 | 2020 | 4734 | 0.200 |
Why?
| Complement System Proteins | 2 | 2022 | 296 | 0.200 |
Why?
| Sickness Impact Profile | 1 | 2020 | 53 | 0.190 |
Why?
| Ranibizumab | 5 | 2013 | 19 | 0.190 |
Why?
| Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.190 |
Why?
| Neurodegenerative Diseases | 1 | 2022 | 98 | 0.190 |
Why?
| Nerve Fibers | 2 | 2010 | 88 | 0.190 |
Why?
| Intravitreal Injections | 6 | 2020 | 47 | 0.180 |
Why?
| Electrodes, Implanted | 2 | 2018 | 99 | 0.180 |
Why?
| Herpesvirus 3, Human | 2 | 2015 | 391 | 0.180 |
Why?
| Protective Factors | 1 | 2019 | 96 | 0.180 |
Why?
| C-Reactive Protein | 1 | 2021 | 363 | 0.180 |
Why?
| Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.170 |
Why?
| Complement C3a | 1 | 2019 | 33 | 0.170 |
Why?
| Odds Ratio | 2 | 2019 | 1043 | 0.170 |
Why?
| Ischemia | 2 | 2017 | 382 | 0.170 |
Why?
| Intraoperative Complications | 1 | 2020 | 132 | 0.170 |
Why?
| Biomarkers | 4 | 2023 | 3662 | 0.170 |
Why?
| Visual Prosthesis | 1 | 2018 | 1 | 0.170 |
Why?
| Quality of Life | 4 | 2022 | 2457 | 0.160 |
Why?
| Cohort Studies | 5 | 2020 | 5294 | 0.160 |
Why?
| Postoperative Complications | 3 | 2021 | 2301 | 0.160 |
Why?
| Orbit | 2 | 2010 | 50 | 0.160 |
Why?
| Metformin | 1 | 2021 | 303 | 0.150 |
Why?
| Anterior Eye Segment | 1 | 2017 | 10 | 0.150 |
Why?
| Labor, Induced | 1 | 2017 | 32 | 0.150 |
Why?
| Reproducibility of Results | 2 | 2023 | 2977 | 0.150 |
Why?
| Strabismus | 1 | 2017 | 27 | 0.150 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2017 | 40 | 0.150 |
Why?
| Laser Coagulation | 3 | 2012 | 58 | 0.150 |
Why?
| Labor, Obstetric | 1 | 2017 | 55 | 0.150 |
Why?
| Giant Cell Arteritis | 2 | 2015 | 47 | 0.150 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2017 | 58 | 0.140 |
Why?
| Time Factors | 4 | 2021 | 6682 | 0.140 |
Why?
| Retinal Degeneration | 2 | 2015 | 28 | 0.140 |
Why?
| Immunosuppressive Agents | 2 | 2013 | 687 | 0.140 |
Why?
| Blindness | 3 | 2013 | 35 | 0.140 |
Why?
| Recovery of Function | 1 | 2019 | 610 | 0.140 |
Why?
| Gyrate Atrophy | 1 | 2015 | 2 | 0.140 |
Why?
| Phenotype | 3 | 2022 | 3070 | 0.140 |
Why?
| Vitreoretinal Surgery | 1 | 2015 | 3 | 0.130 |
Why?
| Case-Control Studies | 2 | 2020 | 3296 | 0.130 |
Why?
| Eye Infections, Bacterial | 1 | 2015 | 25 | 0.130 |
Why?
| Incidence | 2 | 2020 | 2527 | 0.130 |
Why?
| Vitreous Detachment | 1 | 2015 | 6 | 0.130 |
Why?
| Encephalitis, Varicella Zoster | 1 | 2015 | 21 | 0.130 |
Why?
| Needles | 1 | 2015 | 59 | 0.130 |
Why?
| Multivariate Analysis | 1 | 2019 | 1531 | 0.130 |
Why?
| Treatment Outcome | 7 | 2021 | 9692 | 0.130 |
Why?
| Wounds, Gunshot | 2 | 2010 | 178 | 0.130 |
Why?
| Biopsy, Needle | 1 | 2015 | 192 | 0.130 |
Why?
| Oculomotor Muscles | 1 | 2014 | 40 | 0.130 |
Why?
| Antiviral Agents | 2 | 2013 | 670 | 0.130 |
Why?
| Rats, Inbred BN | 3 | 2011 | 51 | 0.130 |
Why?
| Inflammation | 3 | 2023 | 2598 | 0.130 |
Why?
| Proteomics | 1 | 2020 | 890 | 0.120 |
Why?
| Fundus Oculi | 3 | 2014 | 41 | 0.120 |
Why?
| Logistic Models | 1 | 2019 | 1995 | 0.120 |
Why?
| Proteins | 1 | 2020 | 953 | 0.120 |
Why?
| Fibrin | 1 | 2014 | 63 | 0.120 |
Why?
| Adult | 15 | 2020 | 32385 | 0.120 |
Why?
| Uvea | 1 | 2013 | 2 | 0.120 |
Why?
| Exchange Transfusion, Whole Blood | 1 | 2013 | 16 | 0.120 |
Why?
| Uveomeningoencephalitic Syndrome | 1 | 2013 | 6 | 0.120 |
Why?
| Anti-Inflammatory Agents | 2 | 2021 | 469 | 0.120 |
Why?
| Drug Packaging | 2 | 2011 | 45 | 0.120 |
Why?
| Retinal Artery Occlusion | 1 | 2013 | 8 | 0.120 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2013 | 11 | 0.120 |
Why?
| Cytomegalovirus Retinitis | 1 | 2013 | 13 | 0.120 |
Why?
| Tendons | 1 | 2014 | 140 | 0.110 |
Why?
| Premature Birth | 1 | 2017 | 304 | 0.110 |
Why?
| Lymphoproliferative Disorders | 1 | 2013 | 46 | 0.110 |
Why?
| Isoxazoles | 1 | 2013 | 56 | 0.110 |
Why?
| Retinal Pigment Epithelium | 1 | 2013 | 62 | 0.110 |
Why?
| Fatty Acids, Omega-3 | 1 | 2014 | 127 | 0.110 |
Why?
| Silicon | 1 | 2012 | 15 | 0.110 |
Why?
| Lens Subluxation | 1 | 2012 | 3 | 0.110 |
Why?
| Viremia | 1 | 2013 | 133 | 0.110 |
Why?
| Trabecular Meshwork | 1 | 2013 | 77 | 0.110 |
Why?
| Uveitis, Posterior | 1 | 2012 | 12 | 0.110 |
Why?
| Exanthema | 1 | 2013 | 78 | 0.110 |
Why?
| Fluocinolone Acetonide | 1 | 2012 | 16 | 0.110 |
Why?
| Diagnostic Imaging | 1 | 2015 | 310 | 0.100 |
Why?
| Placenta | 1 | 2018 | 648 | 0.100 |
Why?
| Microsurgery | 1 | 2012 | 65 | 0.100 |
Why?
| Diagnosis, Differential | 4 | 2013 | 1423 | 0.100 |
Why?
| Gestational Age | 3 | 2020 | 787 | 0.100 |
Why?
| Electric Stimulation Therapy | 1 | 2012 | 75 | 0.100 |
Why?
| Particulate Matter | 2 | 2011 | 257 | 0.100 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2011 | 68 | 0.100 |
Why?
| Fluorescein-5-isothiocyanate | 2 | 2009 | 38 | 0.100 |
Why?
| Global Health | 1 | 2014 | 352 | 0.100 |
Why?
| Electroretinography | 2 | 2012 | 41 | 0.100 |
Why?
| Silicone Oils | 1 | 2011 | 25 | 0.100 |
Why?
| Drug Storage | 1 | 2011 | 61 | 0.100 |
Why?
| Dextrans | 2 | 2009 | 77 | 0.100 |
Why?
| Dissection | 1 | 2011 | 55 | 0.100 |
Why?
| Glaucoma | 2 | 2010 | 214 | 0.090 |
Why?
| Health Care Costs | 1 | 2014 | 414 | 0.090 |
Why?
| Infliximab | 2 | 2007 | 95 | 0.090 |
Why?
| Anemia, Sickle Cell | 1 | 2013 | 226 | 0.090 |
Why?
| Lysosomal-Associated Membrane Protein 2 | 2 | 2007 | 24 | 0.090 |
Why?
| Antioxidants | 1 | 2014 | 581 | 0.090 |
Why?
| Protein Multimerization | 1 | 2011 | 165 | 0.090 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2009 | 58 | 0.090 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2009 | 50 | 0.090 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 410 | 0.090 |
Why?
| United States | 3 | 2020 | 13272 | 0.090 |
Why?
| Tonometry, Ocular | 1 | 2009 | 92 | 0.090 |
Why?
| Bacteria | 1 | 2015 | 772 | 0.080 |
Why?
| Herpes Zoster | 1 | 2013 | 334 | 0.080 |
Why?
| Scotoma | 1 | 2008 | 4 | 0.080 |
Why?
| Rats | 4 | 2012 | 5426 | 0.080 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 256 | 0.080 |
Why?
| Retinal Artery | 1 | 2007 | 15 | 0.080 |
Why?
| Vitreous Hemorrhage | 1 | 2007 | 6 | 0.080 |
Why?
| Cerebral Angiography | 1 | 2007 | 116 | 0.080 |
Why?
| Acyclovir | 1 | 2007 | 104 | 0.070 |
Why?
| Frameshift Mutation | 1 | 2006 | 28 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 2 | 2009 | 1981 | 0.070 |
Why?
| Conjunctival Neoplasms | 1 | 2005 | 6 | 0.070 |
Why?
| Indocyanine Green | 1 | 2005 | 14 | 0.070 |
Why?
| beta-Thalassemia | 1 | 2006 | 22 | 0.070 |
Why?
| Eye Injuries, Penetrating | 1 | 2005 | 16 | 0.070 |
Why?
| Internationality | 2 | 2018 | 158 | 0.070 |
Why?
| Coloring Agents | 1 | 2005 | 75 | 0.070 |
Why?
| Eye Foreign Bodies | 1 | 2005 | 23 | 0.070 |
Why?
| Secondary Prevention | 1 | 2007 | 257 | 0.070 |
Why?
| Ultrasonography | 2 | 2007 | 740 | 0.070 |
Why?
| Eye Injuries | 1 | 2006 | 46 | 0.070 |
Why?
| Uveitis | 1 | 2006 | 116 | 0.070 |
Why?
| Staining and Labeling | 1 | 2005 | 159 | 0.070 |
Why?
| Antihypertensive Agents | 1 | 2009 | 465 | 0.070 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2007 | 1181 | 0.070 |
Why?
| Pregnancy | 3 | 2018 | 5854 | 0.060 |
Why?
| Metals | 1 | 2005 | 116 | 0.060 |
Why?
| Mydriatics | 1 | 2004 | 3 | 0.060 |
Why?
| Pupil | 1 | 2004 | 15 | 0.060 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 1021 | 0.060 |
Why?
| Sclera | 2 | 2014 | 36 | 0.060 |
Why?
| Hospitals, County | 1 | 2023 | 11 | 0.060 |
Why?
| Young Adult | 6 | 2019 | 11094 | 0.060 |
Why?
| Cardiomyopathy, Dilated | 1 | 2007 | 349 | 0.060 |
Why?
| Sensitivity and Specificity | 2 | 2008 | 1855 | 0.060 |
Why?
| Animals | 6 | 2014 | 34133 | 0.060 |
Why?
| Observer Variation | 1 | 2004 | 314 | 0.060 |
Why?
| Double-Blind Method | 1 | 2007 | 1711 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 839 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2006 | 408 | 0.060 |
Why?
| Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| Interleukin-4 | 1 | 2023 | 230 | 0.050 |
Why?
| Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| Albumins | 1 | 2022 | 104 | 0.050 |
Why?
| Retreatment | 2 | 2012 | 72 | 0.050 |
Why?
| Fibrinogen | 1 | 2022 | 162 | 0.050 |
Why?
| Lenses, Intraocular | 1 | 2021 | 45 | 0.050 |
Why?
| Drug Compounding | 2 | 2011 | 92 | 0.050 |
Why?
| Equipment Design | 2 | 2014 | 533 | 0.050 |
Why?
| Electric Stimulation | 1 | 2021 | 273 | 0.050 |
Why?
| Immunologic Factors | 1 | 2022 | 228 | 0.050 |
Why?
| Chronic Disease | 1 | 2006 | 1645 | 0.050 |
Why?
| RNA, Messenger | 1 | 2007 | 2720 | 0.040 |
Why?
| Cell Survival | 2 | 2013 | 1075 | 0.040 |
Why?
| Postoperative Period | 1 | 2019 | 317 | 0.040 |
Why?
| Melanoma | 1 | 2005 | 709 | 0.040 |
Why?
| Immunity, Maternally-Acquired | 1 | 2018 | 26 | 0.040 |
Why?
| Infant | 3 | 2020 | 8523 | 0.040 |
Why?
| Prevalence | 2 | 2015 | 2442 | 0.040 |
Why?
| Primary Health Care | 1 | 2008 | 1625 | 0.040 |
Why?
| Combined Modality Therapy | 2 | 2013 | 1174 | 0.040 |
Why?
| Infant, Newborn | 2 | 2020 | 5430 | 0.040 |
Why?
| Referral and Consultation | 1 | 2022 | 669 | 0.040 |
Why?
| Iris Diseases | 1 | 2017 | 5 | 0.040 |
Why?
| Choroid Diseases | 1 | 2017 | 9 | 0.040 |
Why?
| Birth Weight | 1 | 2020 | 473 | 0.040 |
Why?
| Parity | 1 | 2017 | 108 | 0.040 |
Why?
| Mental Health | 1 | 2022 | 571 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 690 | 0.040 |
Why?
| Prosthesis Implantation | 1 | 2018 | 148 | 0.040 |
Why?
| Infant, Low Birth Weight | 1 | 2017 | 130 | 0.040 |
Why?
| Microbiological Techniques | 1 | 2015 | 32 | 0.030 |
Why?
| Myopia, Degenerative | 1 | 2015 | 3 | 0.030 |
Why?
| Endotamponade | 1 | 2015 | 4 | 0.030 |
Why?
| Colony Count, Microbial | 1 | 2015 | 124 | 0.030 |
Why?
| Risk | 1 | 2018 | 890 | 0.030 |
Why?
| Tenon Capsule | 1 | 2014 | 3 | 0.030 |
Why?
| Tissue Adhesions | 1 | 2015 | 31 | 0.030 |
Why?
| Adolescent | 3 | 2012 | 18948 | 0.030 |
Why?
| Cerebral Arterial Diseases | 1 | 2015 | 43 | 0.030 |
Why?
| Disease Progression | 2 | 2015 | 2546 | 0.030 |
Why?
| Atrophy | 1 | 2015 | 167 | 0.030 |
Why?
| Biometry | 1 | 2014 | 65 | 0.030 |
Why?
| Conjunctiva | 1 | 2014 | 51 | 0.030 |
Why?
| Lens Implantation, Intraocular | 1 | 2015 | 60 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2022 | 1814 | 0.030 |
Why?
| Fetus | 1 | 2018 | 699 | 0.030 |
Why?
| Hypoglycemic Agents | 1 | 2021 | 1055 | 0.030 |
Why?
| Early Diagnosis | 1 | 2014 | 242 | 0.030 |
Why?
| Safety-net Providers | 1 | 2014 | 106 | 0.030 |
Why?
| Infant, Premature | 1 | 2017 | 507 | 0.030 |
Why?
| Child, Preschool | 1 | 2007 | 9755 | 0.030 |
Why?
| Adaptation, Ocular | 1 | 2012 | 4 | 0.030 |
Why?
| Dark Adaptation | 1 | 2012 | 13 | 0.030 |
Why?
| Rats, Mutant Strains | 1 | 2012 | 24 | 0.030 |
Why?
| Sclerostomy | 1 | 2012 | 3 | 0.030 |
Why?
| Cytomegalovirus | 1 | 2013 | 144 | 0.030 |
Why?
| Mothers | 1 | 2018 | 728 | 0.030 |
Why?
| Drug Implants | 1 | 2012 | 71 | 0.030 |
Why?
| Cell Count | 1 | 2012 | 319 | 0.030 |
Why?
| Gold | 1 | 2012 | 106 | 0.030 |
Why?
| Bruch Membrane | 1 | 2011 | 6 | 0.030 |
Why?
| Polyglycolic Acid | 1 | 2011 | 40 | 0.030 |
Why?
| Swine | 1 | 2014 | 777 | 0.020 |
Why?
| Miniaturization | 1 | 2011 | 24 | 0.020 |
Why?
| Administration, Oral | 1 | 2013 | 786 | 0.020 |
Why?
| Drug Stability | 1 | 2011 | 157 | 0.020 |
Why?
| Delayed-Action Preparations | 1 | 2011 | 162 | 0.020 |
Why?
| Immunoglobulin Light Chains | 1 | 2010 | 35 | 0.020 |
Why?
| Chromatography, Gel | 1 | 2010 | 129 | 0.020 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2010 | 75 | 0.020 |
Why?
| Fluorescein | 1 | 2010 | 28 | 0.020 |
Why?
| Molecular Weight | 1 | 2010 | 346 | 0.020 |
Why?
| Comorbidity | 1 | 2015 | 1600 | 0.020 |
Why?
| Aptamers, Nucleotide | 1 | 2010 | 74 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 336 | 0.020 |
Why?
| Microfluidic Analytical Techniques | 1 | 2010 | 74 | 0.020 |
Why?
| Particle Size | 1 | 2011 | 344 | 0.020 |
Why?
| Lactic Acid | 1 | 2011 | 283 | 0.020 |
Why?
| Reference Values | 1 | 2010 | 789 | 0.020 |
Why?
| Poverty Areas | 1 | 2008 | 37 | 0.020 |
Why?
| Fibroblasts | 1 | 2013 | 846 | 0.020 |
Why?
| Optic Nerve Diseases | 1 | 2008 | 32 | 0.020 |
Why?
| Community Health Centers | 1 | 2008 | 62 | 0.020 |
Why?
| Fluorescent Dyes | 1 | 2010 | 319 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2010 | 884 | 0.020 |
Why?
| Models, Biological | 1 | 2015 | 1756 | 0.020 |
Why?
| Pilot Projects | 1 | 2012 | 1477 | 0.020 |
Why?
| Kidney Transplantation | 1 | 2013 | 584 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2011 | 560 | 0.020 |
Why?
| Imaging, Three-Dimensional | 1 | 2010 | 511 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2015 | 1562 | 0.020 |
Why?
| Pedigree | 1 | 2007 | 492 | 0.020 |
Why?
| Image Processing, Computer-Assisted | 1 | 2010 | 739 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2006 | 396 | 0.020 |
Why?
| Cells, Cultured | 1 | 2013 | 4162 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2008 | 515 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2011 | 2784 | 0.010 |
Why?
| Mass Screening | 1 | 2008 | 1095 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2010 | 2500 | 0.010 |
Why?
| Risk Assessment | 1 | 2008 | 3213 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2012 | 2221 | 0.010 |
Why?
| Aging | 1 | 2008 | 1694 | 0.010 |
Why?
| Mutation | 1 | 2007 | 3493 | 0.010 |
Why?
| Child | 1 | 2012 | 19561 | 0.010 |
Why?
|
|
Mandava's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|